Opaleye Management as of Sept. 30, 2018
Portfolio Holdings for Opaleye Management
Opaleye Management holds 47 positions in its portfolio as reported in the September 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axogen (AXGN) | 12.2 | $48M | 1.3M | 36.85 | |
| Codexis (CDXS) | 7.6 | $30M | 1.8M | 17.15 | |
| Loxo Oncology | 7.6 | $30M | 175k | 170.83 | |
| Amarin Corporation (AMRN) | 6.6 | $26M | 1.6M | 16.27 | |
| Blueprint Medicines (BPMC) | 6.0 | $23M | 300k | 78.06 | |
| Deciphera Pharmaceuticals | 4.1 | $16M | 420k | 38.72 | |
| Polarityte | 3.7 | $15M | 765k | 19.10 | |
| Viking Therapeutics (VKTX) | 3.7 | $14M | 825k | 17.42 | |
| Fibrogen (FGEN) | 3.1 | $12M | 200k | 60.75 | |
| Agios Pharmaceuticals (AGIO) | 2.5 | $10M | 130k | 77.12 | |
| Audentes Therapeutics | 2.3 | $8.9M | 225k | 39.59 | |
| Magenta Therapeutics | 2.2 | $8.7M | 725k | 12.01 | |
| Ptc Therapeutics I (PTCT) | 2.1 | $8.5M | 180k | 47.00 | |
| AMAG Pharmaceuticals | 2.1 | $8.4M | 420k | 20.00 | |
| Strongbridge Bioph shs usd | 2.1 | $8.4M | 1.7M | 4.85 | |
| Sangamo Biosciences (SGMO) | 2.1 | $8.3M | 490k | 16.95 | |
| Fennec Pharmaceuticals (FENC) | 2.0 | $8.0M | 975k | 8.20 | |
| Miragen Therapeutics | 2.0 | $7.8M | 1.4M | 5.58 | |
| Cymabay Therapeutics | 2.0 | $7.7M | 698k | 11.08 | |
| Xenon Pharmaceuticals (XENE) | 1.8 | $7.0M | 465k | 15.08 | |
| Apellis Pharmaceuticals (APLS) | 1.7 | $6.7M | 375k | 17.78 | |
| Xencor (XNCR) | 1.6 | $6.1M | 180k | 34.11 | |
| Ultragenyx Pharmaceutical (RARE) | 1.6 | $6.1M | 80k | 76.34 | |
| Xoma Corp Del (XOMA) | 1.4 | $5.6M | 320k | 17.57 | |
| Ocular Therapeutix (OCUL) | 1.4 | $5.5M | 800k | 6.88 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 1.3 | $5.3M | 1.2M | 4.40 | |
| Corium Intl | 1.3 | $5.2M | 550k | 9.51 | |
| Chimerix (CMRX) | 1.2 | $4.6M | 1.2M | 3.89 | |
| Imprimis Pharmaceuticals | 1.1 | $4.5M | 1.6M | 2.78 | |
| ACADIA Pharmaceuticals (ACAD) | 1.0 | $4.0M | 195k | 20.76 | |
| Iovance Biotherapeutics (IOVA) | 0.9 | $3.7M | 325k | 11.25 | |
| Cti Biopharma | 0.8 | $3.3M | 1.6M | 2.16 | |
| ArQule | 0.8 | $3.1M | 550k | 5.66 | |
| Cara Therapeutics (CARA) | 0.8 | $3.1M | 130k | 23.95 | |
| Cellectis S A (CLLS) | 0.8 | $3.1M | 110k | 28.22 | |
| Ardelyx (ARDX) | 0.7 | $2.8M | 650k | 4.35 | |
| Epizyme | 0.5 | $2.1M | 200k | 10.60 | |
| Tg Therapeutics (TGTX) | 0.5 | $2.0M | 350k | 5.60 | |
| Protalix BioTherapeutics | 0.5 | $1.8M | 2.5M | 0.73 | |
| Clementia | 0.4 | $1.7M | 149k | 11.15 | |
| Tricida | 0.4 | $1.6M | 51k | 30.55 | |
| Dermira | 0.3 | $1.1M | 97k | 10.89 | |
| Biofrontera | 0.3 | $1.1M | 79k | 13.58 | |
| Achillion Pharmaceuticals | 0.3 | $1.0M | 275k | 3.68 | |
| Infinity Pharmaceuticals (INFIQ) | 0.2 | $745k | 275k | 2.71 | |
| Foamix Pharmaceuticals | 0.1 | $521k | 91k | 5.73 | |
| Biolinerx Ltd-spons | 0.1 | $268k | 250k | 1.07 |
